ReviewThe Lancet regional health. Europe2023

The affordability of lecanemab, an amyloid-targeting therapy for Alzheimer's disease: an EADC-EC viewpoint.

Linus Jönsson et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.